Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction.

@article{Baber2007IntratrachealMS,
  title={Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction.},
  author={Syed R Baber and Weiwen Deng and Ryan G Master and Bruce A Bunnell and Bradley K Taylor and Subramanyam N. Murthy and Albert L Hyman and Philip J. Kadowitz},
  journal={American journal of physiology. Heart and circulatory physiology},
  year={2007},
  volume={292 2},
  pages={H1120-8}
}
The administration of mesenchymal stem cells (MSCs) has been proposed for the treatment of pulmonary hypertension. However, the effect of intratracheally administered MSCs on the pulmonary vascular bed in monocrotaline-treated rats has not been determined. In the present study, the effect of intratracheal administration of rat MSCs (rMSCs) on monocrotaline-induced pulmonary hypertension and impaired endothelium-dependent responses were investigated in the rat. Intravenous injection of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 84 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Similar Papers

Loading similar papers…